Study of GDC-0973/XL518 in Patients With Solid Tumors

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: April 18, 2007
Last updated: May 5, 2014
Last verified: May 2014
This non-randomized, open-label, study will determine the highest safe dose of GDC-0973/XL518, how often it should be taken, how well patients with cancer tolerate GDC-0973/XL518 and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.

Condition Intervention Phase
Solid Tumour
Drug: midazolam
Drug: dextromethorphan
Drug: GDC-0973/XL518
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Stage I-II: Safety, tolerability, and maximum tolerated dose of GDC-0973/XL518 [ Time Frame: Through study completion or early study discontinuation ] [ Designated as safety issue: No ]
  • Area under the concentration time curve of midazolam [ Time Frame: Cycle 1: Days 1 and 15 ] [ Designated as safety issue: No ]
  • Stage III: Maximum plasma concentration of dextromethorphan [ Time Frame: Cycle 1: Days 1 and 15 ] [ Designated as safety issue: No ]
  • Stage III: Area under the concentration time curve of dextromethorphan [ Time Frame: Cycle 1: Days 1 and 15 ] [ Designated as safety issue: No ]
  • Stage I-II: Maximum tolerated dose of GDC-0973 [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Stage III: Maximum plasma concentration of midazolam [ Time Frame: Cycle 1: Days 1 and 15 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Stage I-II: Plasma pharmacokinetics and pharmacodynamic effects of GDC-0973/XL518 [ Time Frame: Through study completion or early study discontinuation ] [ Designated as safety issue: No ]
  • Stage III: Safety: incidence of adverse events [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 120
Study Start Date: April 2009
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: midazolam
In Stage III only: single dose of midazolam
Drug: dextromethorphan
In Stage III only: single dose of dextromethorphan
Drug: GDC-0973/XL518
Repeating oral dose


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no known therapies to prolong survival
  • Disease that is measurable according to Response Evaluation Criteria in Solid Tumors (RECIST)
  • Adequate organ and marrow function
  • Sexually active patients must use medically acceptable methods of contraception during the course of the study and at least 11 days after the last dose of study treatment
  • Female patients of childbearing potential must have a negative serum pregnancy test at screening
  • No other history of/or ongoing malignancy that would potentially interfere with the interpretation of the pharmacodynamic or efficacy assays

Exclusion Criteria:

  • Anticancer treatment (e.g., chemotherapy, radiotherapy, cytokines, or hormones) within 28 days (6 weeks for nitrosoureas or mitomycin C, or 14 days for hormonal therapy or kinase inhibitors) before the first dose of study drug
  • The patient has not recovered to Grade </=1 from adverse events (AEs) or to within 10% of baseline values due to investigational or other agents administered more than 28 days prior to study enrollment
  • The patient has received another investigational agent within 28 days of the first dose of study drug
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
  • The patient is pregnant or breastfeeding
  • The patient is known to be positive for the human immunodeficiency virus (HIV)
  • Allergy or hypersensitivity to components of the GDC-0973/XL518 formulation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00467779

United States, California
Los Angeles, California, United States, 90095
Stanford, California, United States, 94305-5821
United States, Michigan
Detroit, Michigan, United States, 48201
United States, New York
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Genentech, Inc.
Study Director: Clinical Trials Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT00467779     History of Changes
Other Study ID Numbers: MEK4592g  GO01329  XL518-001 
Study First Received: April 18, 2007
Last Updated: May 5, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Antitussive Agents
Central Nervous System Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on April 27, 2016